Longevity & Immune
LL-37 (Cathelicidin)
The body's own antimicrobial peptide — the only human cathelicidin, central to innate immune defense and studied for antimicrobial, antibiofilm, wound-healing, and immune-modulating activity. A research compound with a genuinely dual-edged safety profile. Not FDA approved and currently under FDA compounding review; not available to order — join the waitlist.
Coming soon
Get notified when LL-37 (Cathelicidin) launches
LL-37 (Cathelicidin)isn't available to prescribe just yet. Leave your email and we'll let you know the moment it's ready in California — no spam.
Physician-reviewed peptide therapy, prescribed only when appropriate.
Protocol at a glance
- Route
- Subcutaneous injection
- Frequency
- As directed
- Course
- Cyclical course
Physician-reviewed. Prescribed only if appropriate after a telehealth consult — full refund if a licensed clinician determines it isn't right for you.
Why patients choose it
Why researchers are interested in LL-37
Built-in antimicrobial defense
The only human cathelicidin — studied for broad-spectrum activity against bacteria, fungi, and viruses, including antibiofilm effects against drug-resistant organisms.
Wound healing & repair
Research describes roles in angiogenesis, tissue repair, and re-epithelialization, which is why it's investigated in the context of chronic and stubborn wounds.
Immune modulation
Beyond killing microbes directly, LL-37 helps recruit immune cells and shape the inflammatory response — a signaling role at the center of innate immunity.
Overview
What LL-37 is
LL-37 is a 37-amino-acid antimicrobial peptide cleaved from the precursor protein hCAP18 — the single cathelicidin produced by the human body. It is expressed by neutrophils, epithelial cells, and skin as a first-line innate-immune defense, and it does more than one job:
- Direct antimicrobial: disrupts microbial membranes and biofilms across bacteria, fungi, and viruses
- Wound repair: studied for angiogenesis, cell migration, and re-epithelialization
- Immunomodulation: recruits immune cells and tunes the inflammatory response
Most of this evidence is preclinical. Human therapeutic data is limited, and LL-37 is best understood today as a research compound rather than an established treatment.
Safety
The dual-edged biology
LL-37 is genuinely double-sided. The same peptide that is protective in one setting can be pro-inflammatory in another:
- Elevated LL-37 has been implicated in inflammatory skin conditions such as psoriasis and rosacea
- It can act as a self-antigen and amplify inflammation in some autoimmune contexts
- Effects depend heavily on concentration, tissue, and the surrounding immune environment
That complexity is why candidacy, route, and dosing would need careful physician oversight, and why LL-37 is not a routine therapy. Discuss the risk/benefit profile with a licensed physician.
What to expect
How it unfolds, week by week
01
Under review
LL-37 is not available to order. The FDA's Pharmacy Compounding Advisory Committee is scheduled to review it for the 503A bulk-compounding list before the end of February 2027.
02
If a pathway opens
Any future availability would follow a telehealth consult, with a licensed physician assessing whether LL-37 is appropriate given its dual-edged profile.
03
Ongoing
Because the human evidence is still maturing, use would be approached conservatively and individualized — not a fixed protocol.
FAQ
LL-37 questions
Get notified about LL-37
LL-37 is under FDA compounding review and not yet available to order. Join the waitlist and we'll let you know if and when a physician-supervised pathway opens in California.
Join the WaitlistLL-37 (Cathelicidin)
Physician-reviewed